ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $7.1429.

A number of research firms have commented on PRQR. Zacks Research raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Chardan Capital restated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PRQR. Affinity Asset Advisors LLC lifted its stake in ProQR Therapeutics by 6.5% in the 2nd quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock worth $7,139,000 after acquiring an additional 215,000 shares in the last quarter. Aberdeen Group plc grew its stake in ProQR Therapeutics by 24.2% during the 3rd quarter. Aberdeen Group plc now owns 2,298,823 shares of the biopharmaceutical company’s stock valued at $4,896,000 after acquiring an additional 448,475 shares in the last quarter. Sio Capital Management LLC increased its holdings in shares of ProQR Therapeutics by 1.0% in the 2nd quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company’s stock valued at $4,233,000 after purchasing an additional 20,546 shares during the period. ArrowMark Colorado Holdings LLC lifted its position in shares of ProQR Therapeutics by 3.9% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,246,234 shares of the biopharmaceutical company’s stock worth $2,654,000 after purchasing an additional 46,596 shares in the last quarter. Finally, Citadel Advisors LLC lifted its position in shares of ProQR Therapeutics by 73.2% in the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 277,749 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Up 5.2%

Shares of PRQR stock opened at $2.21 on Monday. The stock has a 50-day simple moving average of $2.37 and a 200 day simple moving average of $2.23. The stock has a market capitalization of $232.51 million, a P/E ratio of -4.70 and a beta of 0.17. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 58.70%. The company had revenue of $3.38 million for the quarter, compared to analyst estimates of $7.05 million. On average, sell-side analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.